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197 Clinical follow up after liver transplantation in children with
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Background: 2−10% of children with cystic ﬁbrosis (CF) develop hepatic cirrhosis
with portal hypertension. The liver disease is a signiﬁcant cause of morbidity and
mortality and isolated liver transplantation (LTX) is an excepted therapeutic option.
The effect of LTX on clinical parameters like pulmonary function is still under
discussion.
Patients and Methods: We evaluated clinical parameters of 9 children with CF, at
an age (mean±SD) of 14.1±3 years, before and one year after LTX.
Results: Before liver transplantation all patients had a mild to moderate pulmonary
disease: FVC 92.2±16% (71.4–119%), FEV1 88.7±16.1% (68–103%), MEF25
61.7± 28.5% (35–114%), CN Score 8±4.3 points. They showed a malnutrition:
BMI 17.2±1.8% (15.3%-20.3%), upper arm circumference 17.8±0.9 cm, triceps
skin fat fold 5.2±1.2 cm, 13.5±7.2% of bodyweight were fat. One year after LTX
all patients were in stable pulmonary situation: FVC 93.9±14% (75.5–114%),
FEV1 88.6±12.9% (68–108%), MEF25 61.6±30.4% (24.7–106%), CN Score
7.5±4.8 points. There weren’t any signiﬁcant changes in the airway microbiology
under immunosuppressive therapy (steroid, Ciclosporin±Basilixumab), the serum
IgG levels declined signiﬁcant from 17.4±3.9 g/l to 9.8±2.3/l. The growth over
the year was 6.9±5 cm and the increase of weight come to 5.1±6.1 kg, while the
BMI didn’t increase in this ﬁrst year after transplantation. Certainly we found an
increase of the body fat mass (to 18.2±3.8% of body weight), of the upper arm
circumference (to 20±4.2 cm) und of the Triceps skin fat fold (to 11.4± 8.1 cm).
Conclusions: Liver transplantation is an effective therapy in children with CF
related liver disease and can stabilise pulmonary function and improve nutritional
status in patients with CF and mild or moderate pulmonary involvement before
LTX.
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Aim study was to comparatively assess the value of the ursodeoxycholic acid
(UDCA) treatment in cystic ﬁbrosis associated liver disease (CFLD).
Methods: Study lot included 26 children diagnosed with CFLD-27.95% from all
93 children followed up in our centre. Comparative analysis was done between 2
study groups: group 1 (14 patients, median age at diagnosis 6.6 years), treated with
UDCA; group 2 (12 patients, median age at diagnosis = 14.8 yrs), who did not
receive UDCA. Data were retrospectively evaluated for a period of 2 years (2004–
2006). Groups were aged matched. We assessed the following data: clinical status,
liver function tests (LFT), cholestasis-linked enzymes, abdominal ultrasound (US)
exam, and, in some cases: hepatobiliary scintigraphy, cholangioMRI, liver biopsy.
Patients from group 1 were treated with 20 mg/kilo body weight UDCA.
Results: Among group1, 78.57% (n = 11) patients responded to treatment by
normalization of the LTF and cholestasis-linked enzymes. Better clinical status was
also certiﬁed accompanied by improvement of imagistic data. Only 21.42% from
patients treated with UDCA developed severe LD, comparative to 58.33% untreated
patients. Among group 2, the delay of the diagnosis had a large negative impact on
disease’s natural history. All 12 patients presented with at least one complication;
7 patients with portal hypertension. We have noted worsening of clinical condition
and deterioration of biochemistry and liver imaging in the untreated patients.
Conclusion: The better evolution of the patients treated with UDCA sustain its
recommendation, from the very early diagnosis of liver involvment.
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Aim study is to evaluate the prevalence of gallbladder anomalies in CF children
and its correlation with cystic ﬁbrosis associated liver disease (CFLD).
Methods: Ninety-three hildren aged between 3 month-18 years were evaluated
by abdominal ultrasound examination (US), hepatobiliary scintigraphy and MRI
cholangiography for detection of gallbladder anomalies. Cholestasis-indicating
enzymes, bilirubinemia and liver function test (LFT) were recorded as well. Clinical
examination with a comprehensive anamnesis was performed every visit. Pursued
gallbladder anomalies: microgallbladder, cholelithiasis and cholecistitis.
Results: Gallbladder’s anomalies were detected in 36 cases (38.7%). Microgall-
bladder was the most frequent manifestation – 34.4% (32 patients). Cholelithiasis
occurred in 12 patients (12.9%); in 10 cases microgallbladder was associated (83.3%
reported to cholelitiasis cases). Acalculous cholecystitis was documented in only
2 patients (2.1%). Liver disease was diagnosed in 26 patients (27.95%); ﬁve of them
(19.23%) associated gallbladder anomalies. Among 36 patients with gallbladder
anomalies only 13.88% had liver disease.
Conclusions: Gallbladder disease is a common problem in CF children, with an
increasing incidence. The most prevalent morphological change is microgallbladder.
Cholelithiasis occurs frequently in children with microgallbladder. We have noticed,
without ﬁnding a consistent explanation in this issue, that the gallbladder anomalies
are rare in patients with CFLD and liver disease is uncommon in children with
gallbladder anomalies.
